Why the study?
Does warfarin sodium prevent clinically detectable venous thrombosis or pulmonary embolism compared to dextran 40 in patients following total hip replacement?
Does warfarin sodium prevent clinically detectable venous thrombosis or pulmonary embolism compared to dextran 40 in patients following total hip replacement?
Warfarin and dextran 40 appear equally effective and safe for prophylaxis against venous thromboembolic disease following total hip replacement.
Warfarin and dextran 40 show comparable VTE prophylaxis after hip replacement; supports either agent in practice and future head-to-head trials.
In a prospective randomized study of thromboembolic disease following total hip replacement in 227 patients, the efficacy and safety of prophylaxis by warfarin sodium has been compared with that afforded by dextran 40. No fatal pulmonary emboli occurred. No statistically significant differences existed between the two agents in terms of the frequency of clinically detectable venous thrombosis or pulmonary embolism. Thromboembolic disease occurred in 7.9% of the patients given warfarin and in 10% of the patients given dextran 40. Significant wound bleeding was infrequent and equal in both groups. These two drugs appear equally effective in providing prophylaxis against venous thromboembolic disease following total hip replacement.
No takes yet. Share an insight, caveat, or question.
W. H. Harris (1972) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: